Flare treatment of moderate to severe atopic dermatitis in adults & adolescents ≥16 yr w/ inadequate response to or intolerant of conventional therapies eg, topical corticosteroids. Maintenance treatment of moderate to severe atopic dermatitis for prevention of flares & prolongation of flare-free intervals in patients w/ initial response to max 6 wk of tacrolimus oint bd treatment experiencing high frequency of disease exacerbations ie, occurring ≥4 yrly.
Adult & adolescent ≥16 yr Flare treatment Apply thinly to affected area bd until lesion clearance, reduce frequency or use if clinical condition allows. Maintenance treatment Apply thinly to affected area once daily twice wkly w/ 2-3 days interval.
Discontinue use in absence of clear lymphadenopathy aetiology or in presence of acute infectious mononucleosis. Not to be used in patients w/ congenital or acquired immunodeficiencies or on immunosuppression therapy. Not to be applied to potentially malignant or pre-malignant lesions. Not recommended in patients w/ skin barrier defects eg, Netherton's syndrome, lamellar ichthyosis, generalized erythroderma or cutaneous graft versus host disease. Increased risk of folliculitis & herpes viral infections eg, herpes simplex dermatitis, herpes simplex, Kaposi's varicelliform eruption; lymphomas & skin malignancies in transplant patients; opportunistic infections in immunosuppressed patients; severe burns. Monitor patients who develop lymphadenopathy. Limit exposure to sunlight & avoid use of UV light from solarium; therapy w/ UVB or UVA in combination w/ psoralens. Avoid contact w/ eyes & mucous membranes. Not recommended to be applied under occlusive dressings. Emollients should not be applied to the same area w/in 2 hr. Prolonged & extensive use especially in childn. Hepatic failure. Not to be used during pregnancy. Not recommended during lactation. Not to be used in childn <2 yr.
Sign Out
